Nanotech hep B vaccine could revolutionize therapy

Scientists at the University of Michigan are moving closer to human trials of a new nanoemulsion hepatitis B vaccine that could revolutionize therapy in the third world. The nanoemulsion approach

Other pandemic threats are lurking in H9 virus

H5N1 isn't the only avian virus that threatens to trigger a pandemic. A group of virologists was able to make an H9 virus much more transmissible by changing a single chemical component in the

Woman's immune system may be key to HIV vax

An investigative team at Johns Hopkins has been studying a woman whose natural immunity has quelled the virus she was infected with 10 years ago. Researchers say that she is an 'elite suppressor:'

Vaccine cure for RA heads to human trial

A team of scientists at Newcastle University is preparing a small human trial to test a one-shot approach to curing rheumatoid arthritis with a vaccine devised from a patient's white blood cells. The

New push for meningitis vaccine; Extending flu vaccine protection in the UK;

Vaccine Market A new push by the CDC will help get half of the country's 11 to 18-year olds inoculated with a meningococcal meningitis vaccine, but health officials remain concerned that millions of

Researchers post positive late-stage Heplisav data

Researchers for Dynavax and Merck say that a late-stage trial of their hepatitis B vaccine Heplisav hit the endpoint they were aiming at: non-inferior antibody response compared to GlaxoSmithKline's

Ivins' anthrax attack linked to vaccine criticism?

Federal officials believe that Senator Tom Daschle's objections to the anthrax vaccine being given to soldiers may have been a prime reason why he was targeted in the 2001 anthrax attacks. Daschle

FDA selects flu strains for next round of vaccines

The FDA has come up with a lineup of three all-new flu strains for this year's vaccine recipe. Typically, only one or two strains are changed, but health officials felt that following last season's

IAVI maps out a new route to AIDS vaccine

The head of the International AIDS Vaccine Initiative, Seth Berkley, wants to rewrite the playbook for developing an effective AIDS vaccine. Out: The

Merck, Dynavax announce Heplisav results

Dynavax and Merck announced that their hepatitis B vaccine Heplisav achieved the primary endpoint in a Phase III study. In the study, 95.1 percent of subjects who received Heplisav developed

Vitamin C jab slows growth of cancer

Injecting a large dose of vitamin C into mice started a chain reaction that destroyed cancer cells in mice, according to a research team at the National Institutes of Health. Brain, ovarian and

Would-be partners wage angry feud

The angry exchanges between Emergent BioSolutions and Protein Sciences keep getting nastier. Both companies now accuse each other of breaking their $78 million merger pact, and the accusations are

Fauci says HIV vaccine requires a new approach

The deeply confused state of HIV vaccine research was underscored by NIAID chief Anthony Fauci's recent decision to halt a planned human trial of an experimental jab. In an interview, Fauci pointed

Acambis plots growth after $549M buyout

Sanofi-Aventis' announcement earlier this week that it is buying the UK's Acambis for $549 million is fresh evidence of a buoyant vaccine market. The French drug company is paying a 65 percent

Industry ties to vaccine advocates raises skepticism

Heightened media attention to the financial ties between vaccine makers and the physician groups which advocate their use appears to be encouraging a growing number of parents to

Vaccine may offer protection from black plague

An experimental vaccine created from genetically engineered plant cells appears to be effective against the Black Plague, which has bedeviled the world for centuries and is listed as a top bioterror

NIAID backs Emergent work; Antigenics reports a loss;

Vaccine Research The NIAID has provided $4.5 million in research grants to Emergent BioSolutions for its work on vaccines for botulism and anthrax.

Alzheimer's vax eliminated plaque, not dementia

Researchers are trying to find out why a vaccine for Alzheimer's would be able to eliminate the beta-amyloid plaque long considered responsible for the disease without actually curing the disease.

Merck invests $300M in vaccine expansion

Merck's decision to pump $300 million into an expansion of its Durham, NC vaccine facility is seen by analysts as part of a coordinated effort to solidify a leading role in a booming global vaccines

Dynavax inks universal vaccine pact with Novartis

Dynavax Technologies and Novartis Vaccines and Diagnostics are teaming up on an effort to develop a new universal flu vaccine. Novartis Vaccines, which includes the old Chiron ops it bought out, will